MM cancer

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/30

encourage image

There's no tags or description

Looks like no tags are added yet.

31 Terms

1
New cards

Hallmarks of cancer original 6

sustaining proliferative signaling

evading growth supressors

resisting cell death

enabling replicative immortality

inducing angiogenesis

activating invasion and metastasis

2
New cards

Hallmarks additional 4

deregulating cellular metabolism

evading immune destruction

genome instability

tumor-promoting inflammation

3
New cards

Hallmarks extra 14

phenotypic plasticity & disrupted differentiation

nonmutational epigenetic reprogramming

polymorphic microbiomes

senescent cells in TME

4
New cards

cancer signaling regulates

proliferation, survival, differentiation, metabolism, migration

5
New cards

EGFR/HER2 in gastric cancer

crucial role in growth and spread of GC cells

6
New cards

PI3K/AKt/mTOR in gastric cancer

this pathway is activated due to gene mutations & is involved in tumoral activity

7
New cards

inhibitor classes against cancer pathways

small molecule inhibitors

monoclonal antibodies

immune checkpoint inhibitors

radioimmunotherapy

8
New cards

HER2 in breast cancer

HER2 is important because the signaling promotes :

receptor tyrosine kinase

some breast cancers have amplification.

proliferation, survival, tumor growth, therefore HER2 can become a therapeutic vulnerability.

9
New cards

epidermal growth factor receptors, HER family

what happens when growth factor binds?

all RTKs

receptor activation, receptor dimerization, tyrosine phosphorylation, intracellular signaling, cell proliferation/survival

10
New cards

trastuzumab/Herceptin

why is this useful?

monoclonal antibody targeting HER2

HER2 located on cell surface, antibody can bind extracellular. this then can interfere with signaling and can also recruit immune mechanisms against cancer cell.

11
New cards

Lapatinib

small molecule also important for HER2 signaling

12
New cards

cardiac toxicity of HER2

role in heart cells, so interference with HER2 can cause adverse effects such as cardiac dysfunction in some

13
New cards

cyclin dependent kinase inhibitors

most successful? target? what does it normally do?

effect of inhibitors?

CDK4/6. retinoblastoma protein. normally help control progression through cell cycle. CDK4/6 phosphorylates Rb. this releases E2F. transcription of S-phase genes increases. cell enters S-phase.

now, les Rb phosphorylation, E2F remains suppressed, S-phase entry decreased and cell proliferation is decreased.

this slows cancer proliferation

14
New cards

RAS/ERK/MAPK and Wnt pathways can promote abnormal signaling:

promote tumor development and stem-like properties.

mutations that keep components activated can promote uncontrolled growth

15
New cards

treatment resistance

cancer pathways are interconnected, inhibiting one pathway may not be enough

16
New cards

clonal selection/evolution

tumors are heterogeneic. some clones are sensitive while others aren't, and they survive and keep on growing.

17
New cards

oncogene addiction

cancer cell become heavily dependent on a single dominant oncogene

BCR-ABL in CML targeted by imatinib

EGFR activating mutations (exon 19 deletion) targeted by EGFR TKIs

HER2 amplification in BC, targeted by trastuzumab

KRAS G12C in lung/colon cancer, targeted by inhibitors

18
New cards

passenger mutations

often neutral, can accumulate

19
New cards

driver mutations

provide selective growth advantages

20
New cards

resistance to targeted therapies:

on-target and off-target/bypass resistance

21
New cards

on-target resistance

changes the drug target itself. like a change in the binding pocket, now the drug can’t bind effectively.

22
New cards

off-target/bypass resistance

cancer finds another way to achieve the same biological outcome

23
New cards

phenotypic plasticity

cancer cells can change their cellular identity/state without necessarily acquiring new DNA mutations. this can happen through epigenetic changes, transcriptional rewiring, altered chromatin accessibility.

24
New cards

resistance to targeted therapies

drug transport & metabolism. efflux pumps, drug inactivation/altered metabolism.

DNA damage repair and apoptosis pathways. restoration of HR (important for PARP inhibitors. tumor with BRCA mutation may be sensitive to PARP inhibition initially. but BRCA reversion mutation can restore HR. this way: DNA repair restored —> PARP inhibitor less effective), up regulation of anti-apoptotic proteins.

TME. hypoxia (reducing ROS-mediated killing and inducing HIF signaling), cancer associated fibroblasts secreting HGF which activates MET and bypasses EGFR inhibitor, immune evasion (up regulation of PD-L1 secretion of immunosuppressive cytokines)

25
New cards

secondary resistance mutations: imatinib

ATP pocket mutations: exon 13 (reduces drug binding affinity) and 14 (gatekeeper mutation, interferes with imatinib binding)

activation loop mutation: exon 17/18 (stabilize the kinase in its active conformation) imatinib binds inactive state so now it cannot bind anymore.

26
New cards

mechanisms of resistance for classical kinases:

gatekeeper mutations: change access to ATP pocket

ATP-pocket substitutions: change residues directly involved in drug binding

activation-loop stabilization: force the kinase toward an active conformation

27
New cards

gatekeeper mutation

normally, drug enters pocket, binds kinase, inhibits the kinase.

mutation, amino acid replaced with another residue that has different features. this way it interferes with inhibitor binding. ATP may still bind sufficiently for the kinase activity

examples ABL, where threonine gets changed for isoleucine

EGFR, where threonine gets changed for methionine

KIT, prevents imatinib binding

28
New cards

ATP-pocket substitution

amino acid lining the ATP binding region is altered. ATP might still bind, but the drug now cannot. this creates selective resistance to the drug

29
New cards

A-loop stabilization

the flexible region within a kinase.

different conformations: inactive (associated with DFG out)(A-loop positioned that it blocks substrate binding, gate closed) and active (associated with DFG in)(A-loop moves away, allowing binding, gate open).

DFG motif - Asp-Phe-Gly at the start of the loop. highly conserved in protein kinases.

example EGFR primarily inactive state. upon activation, undergoes transition from inactive monomeric form to active homoodimer.

—> this can cause therapy resistance

30
New cards

clinical strategies to overcome resistance

2nd and 3rd gen inhibitors.

31
New cards

synthetic lethality PARPi + BRCA1/2 mutation

BRCA1/2 mutation causes impairment in HR, but cell may still have other ways to repair DNA.

combining with PARPi, DNA damage accumulates and cancer cell dies.